Migraine Drugs Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,China,Japan - Size and Forecast 2024-2028

Migraine Drugs Market Forecast 2024-2028

The Global Migraine Drugs Market size is estimated to grow by USD 1.34 billion at a CAGR of 6.36% between 2023 and 2028. 

The emergence of regenerative medicines is one of the major factors fuelling the market. In addition, migraine drugs, despite the presence of various highly effective therapies, face a threat due to the lack of curative therapies. Moreover, all drugs that are approved for the treatment of neurologic indications, including migraine, either provide symptomatic relief from the indication or slow down the progression of the indication. Furthermore, no drugs that can reverse the damage caused by the indication and cure the disease have been approved. Therefore, to overcome this challenge, various pharmaceutical companies and research institutions are conducting studies to develop novel regenerative therapies, such as stem cell therapy and gene therapy, for various indications. Hence, such factors are positively impacting the market.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

This market report extensively covers market segmentation by End-user (hospitals, retail, and online), Type (preventive and abortive), and Geography ( North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.

Market Dynamics and Customer Landscape

The market is influenced by various factors, including patient awareness about migraine management and treatment options. Technological advancements contribute to the development of more effective migraine medications. The prevalence of sedentary lifestyles and the increasing incidence among the younger generation drive the demand for drugs. Challenges include the complexity of neurological medical diseases, necessitating the use of diverse medications such as nonsteroidal anti-inflammatory drugs and antipsychotics. Additionally, addressing neurological conditions requires overcoming challenges like osmophobia and sensory disturbances, while ensuring minimal side effects. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

One of the key factors driving the market growth is the increasing number of patients suffering from migraine. The rise in the number of patients suffering from migraine is one of the major factors fuelling the market. In addition, it is a highly prevalent neurological disease across the world. Furthermore, its prevalence is higher in North American regions across the globe. Moreover, the overdose of pain-relief medicines can also lead to migraine-related problems. In addition, the frequent use of some medications can lead to the development of a disabling condition termed medication-overuse headache (MOH).

Furthermore, some of the other reasons that trigger migraine are lack of sleep, hunger, changes in the weather, excessive stimulation of the senses, and stress. Hence, such factors are driving the market growth during the forecast period.

Significant Market Trends

A key factor shaping the market growth is the increasing drug reformulations and repositioning in the pharmaceutical industry. Drug reformulations are one of the significant trends in the market. In addition, drug reformulation is the process of making a change in formulation or repositioning a component of a drug. Furthermore, while most companies reformulate drugs to protect their patent rights, drug reformulations are also a strategy to strengthen the company's portfolio.

Moreover, most drugs that are administered orally or intravenously often face the threat of low patient adherence. In addition, to overcome this, companies are working on increasing patient compliance and the bioavailability of drugs by developing new drug delivery systems, including transdermal patches, ER formulations, and orally disintegrating tablets. Therefore, these new formulations also help companies increase the efficacy of drugs, as novel formulations help drugs reach the targeted site easily. Hence, such factors are driving the market growth.

Major Market Challenges

Concerns related to side effects of migraine drugs are one of the key challenges hindering market growth. There are various concerns related to the side effects of migraine drugs which are negatively impacting the market. In addition, there are various risks associated with the drugs prescribed for migraine.

Moreover, several drugs have side effects, and the most common side effects are drowsiness, weight gain, insomnia, muscle weakness, chest pressure, warm sensations, and agitation. For instance, 5-HT1f drugs such as lasmiditan (Reyvow) work on pain pathways and stop the pain and other bothersome migraine symptoms. In addition, the side effects of these drugs include dizziness, fatigue, tingling, and numbness in the skin. Hence, such factors hinder the market growth during the forecast period.

Buy Now Full Report

Customer Landscape

The market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

Customer Landscape

Market Segmentation by End-user, Type, and Geography Analysis

The market is segmented based on various factors, including technological advancement in pharmaceutical research and development. Specific drug categories such as nonsteroidal anti-inflammatory drugs (NSAIDs), pain-relieving medications, and blood pressure-lowering medications cater to different aspects of migraine management. Anticonvulsant drugs play a crucial role in managing neurological conditions associated with migraines. Moreover, the market addresses symptoms like loss of appetite and neurological manifestations caused by factors such as viruses affecting the nervous system. Additionally, there's a focus on addressing related health issues such as cardiac diseases, pulmonary diseases, and vascular diseases that may exacerbate symptoms.

End-user Analysis

Hospitals

The hospitals segment is estimated to witness significant growth during the forecast period. The hospital segment in the market is fuelled by the increasing prevalence and diagnosis of migraine and the increasing number of public and private specialty hospitals and clinics. In addition, large hospitals and clinics are equipped with advanced medical infrastructure and procure high-quality medical products and consumables in bulk. Furthermore, several advancements in treatment are fuelling the growth of this segment.

Get a glance at the market contribution of various segments Download PDF Sample

The hospitals segment was the largest segment and was valued at USD 1.18 billion in 2018. For instance, in April 2023, the US Food and Drug Administration (FDA) approved expanding the indication of QULIPTA (atogepant) for the preventive treatment of migraine in adults, thereby increasing their demand in healthcare facilities such as hospitals and clinics. In addition, factors that are positively influencing segmental growth are an increase in admissions of patients with migraine symptoms such as unilateral or throbbing pain in the forehead, side of the head, or around the eyes, nausea, vomiting, photophobia, and phonophobia, which can increase the demand for migraine drugs. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Type Analysis

Preventive

The preventive treatment segment in market is fuelled by its treatment of reducing the attack frequency and the severity of migraine. In addition, preventive or prophylactic treatment includes the prescription of off-label and generic medications that include beta-blockers such as propranolol and atenolol. Moreover, preventive drugs are taken regularly, often daily, to reduce the severity or frequency of migraine. In addition, preventive medications help in increasing the effectiveness of the symptom-relieving medicines used during migraine attacks. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Abortive

There is significant growth in the abortive treatment or acute treatment segment in the market due to its pain-relieving medication treatment for migraine. In addition, the availability of abortive treatment for migraine has increased over the years. Moreover, abortive treatment for migraine can be classified as specific and non-specific treatment. In addition, the non-specific treatment includes analgesics and non-steroidal anti-inflammatory drugs. Furthermore, the abortive drugs that are taken under the prescription or guidance of the doctors will function as an acute treatment for migraine. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Factors such as the presence of a well-established healthcare system that provides high-quality migraine therapeutics, primarily through its clinics and hospitals are fuelling the market growth in North America. In addition, the increasing healthcare expenditure in countries such as the US and Canada is another factor that enhances the growth in the migraine drugs market in the region. Moreover, some of the major companies that offer migraine therapeutics across North America are Amgen, Eli Lilly and Company, and Novartis. In addition, there are various strategic collaborations between the vendors for increasing the commercialization of migraine therapeutics in North America. Furthermore, there is also an increased presence of FDA-approved drugs for the treatment of migraines in North America. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers migraine drugs that help patients whose frequent disabling attacks negatively impact the performance of daily activities.

Abbott Laboratories, Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck and Co. Inc., Neurelis Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Winston Pharmaceuticals Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• End-user Outlook
  • Hospitals
  • Retail
  • Online
• Type Outlook
  • Preventive
  • Abortive
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview 

The market addresses a range of challenges linked to neurological medical diseases and related conditions like neurological manifestations, fever, and sleep disturbances. Pharmaceutical interventions include nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and antiepileptics for acute therapy and oral preventive treatment. Triptans, beta-blockers, and small molecules are also utilized for managing chronic migraines and their chronic effects, such as anxiety and depression. As researchers delve into the epidemiology, etiology, and pathophysiology of migraines, advancements in treatment aim to address underlying causes like olfactory groove disruptions and dehydration, ultimately improving prophylaxis and patient outcomes.

Additionally, the market tackles the complexities of neurological medical diseases and associated conditions like neurological manifestations, sleep disturbances, and headaches. Pharmaceutical interventions encompass a spectrum of options including nonsteroidal anti inflammatory drugs (NSAIDs), anti epileptics, and beta blockers for managing chronic migraines. Additionally, blood pressure-lowering medications play a crucial role in alleviating migraine symptoms by addressing underlying vascular factors. Understanding the role of the virus and its impact on the neurologic manifestations is vital in developing targeted therapies. With a focus on analgesia and improved treatment outcomes, advancements in migraine drugs aim to provide relief to patients, particularly males who are susceptible to chronic migraine conditions.

Market Scope
Report Coverage	Details
Page number	168
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.36%
Market Growth 2024-2028	USD 1.34 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	6.22
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Canada, Germany, China, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck and Co. Inc., Neurelis Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Winston Pharmaceuticals Ltd.
Market dynamics	Parent market growth analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the  market between 2024 and 2028
• Precise estimation of the market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch